Basic Information
| LncRNA/CircRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 |
| Ensemble | ENSG00000177640 |
| Refseq | NR_026939 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot, Luciferase Reporter Assays |
| Sample | cervical cancer tissues, cell lines (SiHa, Me180, HCE1, HeLa and CaSki) |
| Expression Pattern | down-regulated |
| Function Description | In this study, CASC2 expression was down-regulated in cervical cancer tissues, and was related to a shorter survival time and poore clinicopathologic features. Taken together, these observations suggest CASC2 up-regulates PTEN as a ceRNA of miR-21 and plays an important role in cervical cancer sensitivity to DDP and may serve as a potential target for cancer diagnosis and treatment. |
| Pubmed ID | 28495512 |
| Year | 2017 |
| Title | Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin |
External Links
| Links for CASC2 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |